PO.1.5 Scoring personalized molecular portraits identify systemic lupus erythematosus subtypesand predict transcriptional drug responses, symptomatology and disease progression. (27th September 2022)

• Record Type: Journal Article
• Authors: Toro Dominguez, D; Martínez Bueno, M; López Domínguez, R; Martorell Marugan, J; Carnero Montoro, E; Barturen, G; Goldman, D; Petri, M; Carmona Saez, P; Alarcón-Riquelme, M
• Is Part Of: Lupus science & medicine. Volume 9(2022)Supplement 2
• Page Start: A25
• Page End: A26
• Publication Date: 2022-09-27
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2022-elm2022.39
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Purpose: Systemic Lupus Erythematosus is a complex autoimmune disease that leads to important worsening of quality of life and mortality. Flares appear unpredictably during the disease course and therapies used are often only partially effective. These challenges are mainly due to the molecular heterogeneity of the disease, such that personalized medicine offers major promise. With this work we intended to advance in that direction by developing My PROSLE, an omics-based workflow for measuring the molecular portrait of individual patients to support clinicians in their therapeutic decisions. Methods: Immunological gene-modules were used to represent the transcriptome of the patients. A dysregulation score for each gene-module was calculated at the patient level based on averaged z-scores. Almost 4300 lupus and 750 healthy samples were used to analyze the association between dysregulation scores, clinical manifestations, prognosis, flare and remission events and transcriptional drug response to Tabalumab. Machine learning-based classification models were built to predict around 90 different clinical parameters based on personalized dysregulation scores. Results: My PROSLE allows to molecularly summarize patients in 206 gene-modules, clustered into 9 main lupus signatures (Example in figure 1, the combination of which revealed highly differentiated pathological mechanisms. We show that dysregulation of certain gene-modules is strongly associated with specific clinical manifestations, the occurrence of relapses or the potential presence of long-term remission and drug response. Therefore, My PROSLE could be used to accurately predict these clinical outcomes. Conclusions: My PROSLE (https://myprosle.genyo.es) allows molecular characterization of individual Lupus patients and it extracts key molecular information to support more precise therapeutic decisions.